Clinical Trial to Evaluate the Tolerance of TQB3201 Tablets

NCT07172126 | Not Yet Recruiting Phase 1

• 1 other identifier: TQB3201-I/II-01
• Study Type: interventional
• Target: 291
• Locations: 1 country
• Sites: 3

Brief Summary

TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to Androgen Receptor (AR) and the other end to a ligand of E3 ligase (CRBN) via a linker. The phase I phase of this trial aims to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3201 tablets for the treatment of advanced prostate cancer.

Conditions

Metastatic Castration-resistant Prostate Cancer

Outcome Measures

Primary Outcomes (4)

• Dose Limiting Toxicity (DLT)

  DLTs are defined as toxicities that occur from the first dose to the end of the first treatment cycle by the severity criteria related to the trial drug (according to Common Terminology Criteria for Adverse Events v5.0 toxicity evaluation criteria) .

  Up to 28days

• Maximum tolerated dose (MTD)

  The MTD was defined as the highest dose in ≥ 6 evaluable subjects without any of the following: 1. In the DLT evaluation window, DLT occurred in 2 out of 3 subjects; 2. In the DLT evaluation window, 1 of the first 3 subjects had DLT, and 3 more subjects were added and 1 case had ≥ DLT.

  Up to 28days

• Phase II Recommended Dose (RP2D)

  The RP2D will be determined based on the safety and tolerability information of the Phase I dose escalation phase and the efficacy and safety information of the Phase II phase.

  Up to 2 years

• Radiographic progression-free survival (rPFS)

  The time from randomization to the first occurrence of either radiologically confirmed disease progression or death from any cause, whichever comes first.

  Up to 2 years

Secondary Outcomes (11)

• Adverse events (AEs)

  Up to 2 years

• The area under the curve (AUC)

  cycle1 day1pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose, cycle1 day7, 14 pre-dose, cycle1 day 28 pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose

• Peak concentration (Cmax)

  cycle1 day1pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose, cycle1 day7, 14 pre-dose, cycle1 day 28 pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose

• Terminal half-life (T1/2)

  cycle1 day1pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose, cycle1 day7, 14 pre-dose, cycle1 day 28 pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose

• Apparent Clearance (CL/F)

  cycle1 day1pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose, cycle1 day7, 14 pre-dose, cycle1 day 28 pre-dose, 0.5, 1, 2, 3, 4, 6, 9, 12, 24 hours after dose

Study Arms (1)

TQB3201 tablets

EXPERIMENTAL

Each enrolled subject received 28 consecutive days of administration, once daily after meals. (25mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg)

Drug: TQB3201 tablets

Interventions

TQB3201 tablets DRUG

TQB3201 is an orally administered targeted protein chimera (PROTAC) drug in which one end of the drug is attached to a ligand that binds to AR and the other end to a ligand of E3 ligase (CRBN) via a linker. This product is effective against anti-androgen drugs (such as abiraterone, enzalutamide, etc.) resistance mutations, including AR amplification, point mutations (L702H, H875Y, T878A mutations, etc.), and can target the degradation of wild-type AR and AR ligand-binding domain mutants, especially L702H mutations, which is a new generation of AR-PROTAC.

TQB3201 tablets

Eligibility Criteria

• Age: 18 Years+
• Sex: male
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Histologically or cytologically confirmed adenocarcinoma of the prostate;
• Age≥ 18 years old (calculated from the date of signing the informed consent form);
• Eastern Cooperative Oncology Group Performance Status(ECOG )score 0-1 points;
• Presence of metastatic disease confirmed by imaging;
• Serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) at screening;
• Sufficient samples should be provided for gene mutation detection to determine androgen receptor gene status.
• Patients who have progressed on the basis of at least 1 new endocrine drug;
• The laboratory inspection meets the following standards:
• Hemoglobin (HGB) ≥90g/L;
• Absolute neutrophil value (NEUT) ≥1.5×109/L;
• Platelet count (PLT) ≥75×109/L.
• Total bilirubin (TBIL) ≤2 times the upper limit of normal (ULN); (3×ULN for patients with Gilbert syndrome ≤);
• Alanine transferase (ALT) and aspartate transferase (AST) ≤2.5× ULN. If accompanied by liver metastasis, ALT and AST ≤ 5× ULN;
• Serum creatinine (CR) ≤1.5× ULN or creatinine clearance estimated by the Cockcroft-Gault glomerular filtration formula ≥ 60 mL/min.
• Urine routine: urine protein \<; If the urine protein is ≥, the 24-hour urine protein quantitative ≤ 1.0 g should be confirmed.

You may not qualify if:

• Subjects with brain metastases with symptoms or symptom control time of less than 1 month;
• Within 5 years before the first dose of medication or other malignant tumors at the same time.
• Imaging ( Computed Tomography or Magnetic Resonance Imaging) shows that the tumor/metastasis has invaded important blood vessels, or the tumor/metastasis is very likely to invade important blood vessels during the follow-up study period, causing major bleeding;
• Severe bone damage caused by bone metastasis; Pathological fractures and spinal cord compression of important parts that occurred within the past 6 months or are expected to occur in the near future as judged by the investigator;
• Pleural effusion, pericardial effusion or ascites that cannot be controlled and still needs to be repeatedly drained (judged by the investigator);
• Diseases affecting intravenous injection and intravenous blood collection, or having multiple factors affecting oral drugs (such as inability to swallow, chronic diarrhea and intestinal obstruction, etc.);
• Adverse reactions of previous treatment have not recovered to Common Terminology Criteria (CTC) adverse event (AE) v5.0 grade ≤1, except for grade 2 alopecia, grade 2 peripheral neurotoxicity, grade 2 anemia, non-clinically significant and asymptomatic laboratory abnormalities, hypothyroidism stable on hormone replacement therapy, and other toxicities judged by the investigator to have no safety risk;
• Have previously used or plan to use other similar drugs during the study;
• Those who have received surgery, radiotherapy, radiotherapy, or local therapy (such as radiofrequency ablation, freezing, high-energy focused ultrasound, etc.) for prostate cancer after being diagnosed with metastatic prostate cancer;
• Previous use of 5-ɑ reductase inhibitors within 4 weeks before the first dose; Systemic treatment with estrogens, progesterones, steroids (except for temporary use for anti-allergic use); First-generation AR antagonists; targeted therapy; biological therapy; immunotherapy; nuclide therapy; Botanicals known to have antitumor or PSA-lowering effects; Study treatments in other clinical trials.
• Those who have undergone major surgical treatment, obvious traumatic injuries, or are allowed to undergo major surgery during the expected study treatment period within 4 weeks before the first dose, or have long-term unhealed wounds or fractures. (Major surgery is defined as: surgery of grade 3 or above in the 2022 edition of the National Surgical Grading Catalogue).
• Subjects with any bleeding or bleeding event ≥Common Terminology Criteria for Adverse Events（CTCAE ）grade 3 within 4 weeks before the first dose.
• Active viral hepatitis with poor control.
• Active syphilis infection requiring treatment; Presence of active tuberculosis, history of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, radiation pneumonitis requiring treatment, or active pneumonitis with clinical symptoms; Active or uncontrolled serious infection (≥CTC AE grade 2 infection);
• Those who have a history of psychotropic substance abuse and cannot abstain from it, or have mental disorders or have a history of drug use.

Sponsors & Collaborators

• Chia Tai Tianqing Pharmaceutical Group Co., Ltd.: lead

Study Sites (3)

Cancer Hospital Affiliated to Chongqing University

Chongqing, Chongqing Municipality, 400000, China

Location

The Fifth Affiliated Hospital of Sun Yat-sen University

Zhuhai, Guangdong, 519000, China

Location

Cancer Hospital Affiliated to Fudan University

Shanghai, Shanghai Municipality, 201321, China

Location

Central Study Contacts

Dingwei Ye, Doctor

CONTACT

13701663571; dwyeli@163.com

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 8, 2025
• First Posted: September 15, 2025
• Study Start: September 1, 2025
• Primary Completion (Estimated): April 1, 2027
• Study Completion (Estimated): December 1, 2028
• Last Updated: September 15, 2025

Record last verified: 2025-04

Locations

CN (3)